Search results
Promising melanoma therapy could be the next major advancement in cancer treatment
NBC News via Yahoo News· 2 years agoAn experimental treatment for advanced melanoma is poised to be the next major advance in cancer...
New cell-based therapy for melanoma more effective than existing treatment, trial finds
NBC News via Yahoo News· 2 years agoEuropean researchers announced Saturday that a new treatment for advanced melanoma was more...
Iovance, with approval of ‘TIL’ cell therapy, readies for complex launch
BioPharma Dive via Yahoo Finance· 4 months agoThe biotech set a price of roughly $515,000 per patient for its therapy Amtagvi, the first to be...
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
Zacks via Yahoo Finance· 5 months agoShares of Instil Bio, Inc. TIL have rallied 22.2% in the past week against the industry’s decrease...
Test may identify which breast cancer patients can safely skip chemo
United Press International via Yahoo News· 2 months agoWomen with early-stage triple-negative breast cancer appear to have better survival rates and a...
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
Motley Fool via Yahoo Finance· 4 months agoInvestors looking for stocks that can produce swift and dramatic gains recently found what they...
Why Iovance Stock Is Down 18% Today
Motley Fool via Yahoo Finance· 1 month agoIovance Biotherapeutics (NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The...
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Motley Fool via Yahoo Finance· 4 days agoIt's always a nice surprise to see that a company you're invested in is making good on its...
Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Simply Wall St. via Yahoo Finance· 2 months agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA) is possibly approaching a major achievement in its...
Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock
Benzinga via Yahoo Finance· 2 years agoHC Wainwright initiated coverage of Lyell Immunopharma Inc (NASDAQ: LYEL) with a Buy rating and a...